MCL1 and neoplasm: These observations, together with our results presented here, suggest that inhibiting CDK9 would suppress tumor-initiating embryonic stem cell transcription factors and survival proteins like Mcl1, to overcome NSCLC growth and drug resistance (Figure 8G, schematic).